Efficacy of Imatinib Mesylate in Patients with Liver Metastases from Gastrointestinal Stromal Tumor Failing Intra-Arterial Hepatic Chemotherapy with Epirubicin

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 4 SUPPL., 2003, Pages 13-16

  Fiorentini, Giammaria ^a   Bernardeschi, P ^a   De Simone, M ^a   Rossi, S ^a   Dentico, P ^a   Biancalani, M ^a   Scuderi, S ^a   Vaira, M ^a   Palomba, A ^a  

^a SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Epirubicin; GIST; Imatinib mesylate; Intra arterial; Liver metastases

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EYELID EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOLOGY; HUMAN; LIVER METASTASIS; MALE; NEUTROPENIA; OMENTOPLASTY; PRIORITY JOURNAL; RASH; SYMPTOM; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS; EPIRUBICIN; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 1842583424     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Shaldenbrand J.D., Appelman H.D.: Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation. Hum. Pathol. 15:229-232 1984.
2. Hirota S., Isozaki K., Moriyama Y., et al: Gain-of-function mutations of c-KIT in human gastrointestinal stromal stromal tumor. Science 279:577-580, 1998.
3. Van Oosterom A.T., Judson I., Verweij J., et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001.
4. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al: Effect o the tyrosine Kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:1052-1056, 2001.
5. Ng E.H., Pollock R.E., Munsell M.F., et al: Prognostic factors influencing survival in gastrointestinal leyomiosarcomas. Implications for surgical management and staging. Ann. Surg. 215:68-77, 1992.
6. De Matteo R.P., Lewis J.I., Leung D., et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann. Surg. 231:51-57, 2000.
7. Van Glabbeke M., Van Oosterom A.T., Oosterhuis J.W., et al: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens. A European Organization for research and Treatment of Cancer Soft Tissue and Bone sarcoma Group study. J. Clin. Oncol. 17:150-157, 1999.
8. Rajan D.K., Soulen M.C., Clark T.W., et al: Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, etiodol, and polyvinyl alcohol chemoembolization. J. Vasc. Interv. Radiol. 12:187-193, 2001.
9. Mavligit G.M., Zukwiski A.A., Ellis L.M., et al: Gastrointestinal leiomyosarcoma metastatic to the liver: Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 75:2083-2088, 1995.
10. Blanke C.D., Von Mehren M., Joensu H. et al: Evaluation of the molecularly targeted therapy STI 571 in patients with unresctable or metastatic gastrointestinal stromal tumors expressing KIT. ASCO Proc 20:2,2001.
11. Eisen T.: Thalidomide in solid malignancies. J. Clin. Oncol. 20:2607-2609, 2002.
12. Demetri G.D., Von Mehren M., Blanke C.D., et al.: Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New. Engl. J. Med. 347:472-480, 2002.